AtonRa Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | $510K | Sell |
2,662
-273
| -9% | -$52.3K | 1.02% | 34 |
|
|
2023
Q3 | $520K | Sell |
2,935
-675
| -19% | -$120K | 1.09% | 24 |
|
|
2023
Q2 | $686K | Sell |
3,610
-158
| -4% | -$30K | 1.06% | 26 |
|
|
2023
Q1 | $755K | Sell |
3,768
-485
| -11% | -$97.2K | 1.1% | 27 |
|
|
2022
Q4 | $1.01M | Sell |
4,253
-1,776
| -29% | -$422K | 1.29% | 22 |
|
|
2022
Q3 | $1.21M | Sell |
6,029
-43
| -0.7% | -$8.61K | 1.19% | 23 |
|
|
2022
Q2 | $886K | Sell |
6,072
-3,509
| -37% | -$512K | 0.81% | 49 |
|
|
2022
Q1 | $1.56M | Buy |
9,581
+149
| +2% | +$24.3K | 0.85% | 48 |
|
|
2021
Q4 | $1.6M | Buy |
9,432
+748
| +9% | +$127K | 0.56% | 64 |
|
|
2021
Q3 | $1.64M | Buy |
8,684
+587
| +7% | +$111K | 0.55% | 75 |
|
|
2021
Q2 | $1.37M | Sell |
8,097
-12,113
| -60% | -$2.05M | 0.5% | 72 |
|
|
2021
Q1 | $2.85M | Buy |
20,210
+12,820
| +173% | +$1.81M | 1.27% | 25 |
|
|
2020
Q4 | $960K | Buy |
+7,390
| New | +$960K | 0.47% | 68 |
|